A recent study by the Indian Council of Medical Research announced that Bharat Biotech’s Covaxin is effective against the prevailing Delta Plus variant of COVID-19. The vaccine which was developed by Bharat Biotech in collaboration with the ICMR National Institute of Virology (NIV), reportedly, demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
Meanwhile, addressing the issue of the COVID-19 vaccine Covaxin used in India not being recognised by many countries, Minister of State for Health Bharati Pravin Pawar said that the government is aware that Covaxin at present is not part of WHO Emergency Use Listing (EUL). Nonetheless, a review process by WHO has commenced, which will take up to six weeks to decide on Emergency Use Listing (EUL) submissions.
(Internet Inputs)